BACKGROUND: A DNA methylation signature has been characterized that distinguishes rheumatoid arthritis (RA) fibroblast like synoviocytes (FLS) from osteoarthritis (OA) FLS. The presence of epigenetic changes in long-term cultured cells suggest that rheumatoid FLS imprinting might contribute to pathogenic behavior. To understand how differentially methylated genes (DMGs) might participate in the pathogenesis of RA, we evaluated the stability of the RA signature and whether DMGs are enriched in specific pathways and ontology categories. METHODS: To assess the RA methylation signatures the Illumina HumanMethylation450 chip was used to compare methylation levels in RA, OA, and normal (NL) FLS at passage 3, 5, and 7. Then methylation frequencies at CpGs within the signature were compared between passages. To assess the enrichment of DMGs in specific pathways, DMGs were identified as genes that possess significantly differential methylated loci within their promoter regions. These sets of DMGs were then compared to pathway and ontology databases to establish enrichment in specific categories. RESULTS: Initial studies compared passage 3, 5, and 7 FLS from RA, OA, and NL. The patterns of differential methylation of each individual FLS line were very similar regardless of passage number. Using the most robust analysis, 20 out of 272 KEGG pathways and 43 out of 34,400 GO pathways were significantly altered for RA compared with OA and NL FLS. Most interestingly, we found that the KEGG 'Rheumatoid Arthritis' pathway was consistently the most significantly enriched with differentially methylated loci. Additional pathways involved with innate immunity (Complement and Coagulation, Toll-like Receptors, NOD-like Receptors, and Cytosolic DNA-sensing), cell adhesion (Focal Adhesion, Cell Adhesion Molecule), and cytokines (Cytokine-cytokine Receptor). Taken together, KEGG and GO pathway analysis demonstrates non-random epigenetic imprinting of RA FLS. CONCLUSIONS: The DNA methylation patterns include anomalies in key genes implicated in the pathogenesis of RA and are stable for multiple cell passages. Persistent epigenetic alterations could contribute to the aggressive phenotype of RA synoviocytes and identify potential therapeutic targets that could modulate the pathogenic behavior.
BACKGROUND: A DNA methylation signature has been characterized that distinguishes rheumatoid arthritis (RA) fibroblast like synoviocytes (FLS) from osteoarthritis (OA) FLS. The presence of epigenetic changes in long-term cultured cells suggest that rheumatoid FLS imprinting might contribute to pathogenic behavior. To understand how differentially methylated genes (DMGs) might participate in the pathogenesis of RA, we evaluated the stability of the RA signature and whether DMGs are enriched in specific pathways and ontology categories. METHODS: To assess the RA methylation signatures the Illumina HumanMethylation450 chip was used to compare methylation levels in RA, OA, and normal (NL) FLS at passage 3, 5, and 7. Then methylation frequencies at CpGs within the signature were compared between passages. To assess the enrichment of DMGs in specific pathways, DMGs were identified as genes that possess significantly differential methylated loci within their promoter regions. These sets of DMGs were then compared to pathway and ontology databases to establish enrichment in specific categories. RESULTS: Initial studies compared passage 3, 5, and 7 FLS from RA, OA, and NL. The patterns of differential methylation of each individual FLS line were very similar regardless of passage number. Using the most robust analysis, 20 out of 272 KEGG pathways and 43 out of 34,400 GO pathways were significantly altered for RA compared with OA and NL FLS. Most interestingly, we found that the KEGG 'Rheumatoid Arthritis' pathway was consistently the most significantly enriched with differentially methylated loci. Additional pathways involved with innate immunity (Complement and Coagulation, Toll-like Receptors, NOD-like Receptors, and Cytosolic DNA-sensing), cell adhesion (Focal Adhesion, Cell Adhesion Molecule), and cytokines (Cytokine-cytokine Receptor). Taken together, KEGG and GO pathway analysis demonstrates non-random epigenetic imprinting of RA FLS. CONCLUSIONS: The DNA methylation patterns include anomalies in key genes implicated in the pathogenesis of RA and are stable for multiple cell passages. Persistent epigenetic alterations could contribute to the aggressive phenotype of RA synoviocytes and identify potential therapeutic targets that could modulate the pathogenic behavior.
Authors: Mar Carrión; Yasmina Juarranz; Selene Pérez-García; Rebeca Jimeno; José L Pablos; Rosa P Gomariz; Irene Gutiérrez-Cañas Journal: Arthritis Rheum Date: 2011-06
Authors: Stephanie Lefèvre; Anette Knedla; Christoph Tennie; Andreas Kampmann; Christina Wunrau; Robert Dinser; Adelheid Korb; Eva-Maria Schnäker; Ingo H Tarner; Paul D Robbins; Christopher H Evans; Henning Stürz; Jürgen Steinmeyer; Steffen Gay; Jürgen Schölmerich; Thomas Pap; Ulf Müller-Ladner; Elena Neumann Journal: Nat Med Date: 2009-11-08 Impact factor: 53.440
Authors: Emon Elboudwarej; Michael Cole; Farren B S Briggs; Alexandra Fouts; Pamela R Fain; Hong Quach; Diana Quach; Elizabeth Sinclair; Lindsey A Criswell; Julie A Lane; Andrea K Steck; Lisa F Barcellos; Janelle A Noble Journal: J Autoimmun Date: 2016-01-09 Impact factor: 7.094
Authors: Keisuke Maeshima; Stephanie M Stanford; Deepa Hammaker; Cristiano Sacchetti; Li-Fan Zeng; Rizi Ai; Vida Zhang; David L Boyle; German R Aleman Muench; Gen-Sheng Feng; John W Whitaker; Zhong-Yin Zhang; Wei Wang; Nunzio Bottini; Gary S Firestein Journal: JCI Insight Date: 2016-05-19
Authors: Carl Orr; Elsa Vieira-Sousa; David L Boyle; Maya H Buch; Christopher D Buckley; Juan D Cañete; Anca I Catrina; Ernest H S Choy; Paul Emery; Ursula Fearon; Andrew Filer; Danielle Gerlag; Frances Humby; John D Isaacs; Søren A Just; Bernard R Lauwerys; Benoit Le Goff; Antonio Manzo; Trudy McGarry; Iain B McInnes; Aurélie Najm; Constantino Pitzalis; Arthur Pratt; Malcolm Smith; Paul P Tak; Rogier Thurlings; João E Fonseca; Douglas J Veale; Sander W Tas Journal: Nat Rev Rheumatol Date: 2017-07-13 Impact factor: 20.543